Anika Therapeutics, Inc.

NASDAQ:ANIK

Medical - Devices

Healthcare
$13.62 -0.39%

-$0.06 today

Market cap
$182.44M
Beta
0.23
P/E (TTM)
-17.3
EPS (TTM)
-$0.82
52W Low $7.87High $16.24

Volume 0.12M

Average 0.11M

ANIK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Anika Therapeutics, Inc.NASDAQ: ANIK

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $6.71M rose 10.8% year over year, behind the +16.3% change in trailing-twelve-month research & development. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.

Context

  • Research & development amounted to 22.8% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.8% toward the trailing-twelve-month pace of +16.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.71M+4.0% QoQ
Last fiscal yearDec 2025
$25.77M+0.9% YoY
LTMMar 2026
$26.42M+16.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year+0.9%——
3-year CAGR+12.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
25.77M USD
Year-over-year change
+0.9%
4-year CAGR
-1.5%

Research & Development vs competitors

How ANIK compares with its peers on the latest reported figures

  • ANIK's LTM Mar 2026 research & development of $26.42M is the 2nd highest of the 9 companies compared; the peer median is $9.41M.
  • Its year-over-year change of +16.3% is the 3rd highest of 9, against a peer median of -7.5%.
  • Research & development amounts to 22.7% of revenue for ANIK, versus a peer median of 38.8%.
ANIK Competitors Peer median
Research & Development for ANIK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M +24.4%+57.8%3788.3%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$26.42M +16.3%+12.0%22.7%
MXCTMaxCyte, Inc.LTM Mar 2026$18.78M -12.5%+2.2%58.2%
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
LNSRLENSAR, Inc.LTM Mar 2026$5.47M +1.0%-21.9%9.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
ANIXAnixa Biosciences, Inc.LTM Apr 2026$4.56M -27.4%-8.9%—
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
Peer median (excluding ANIK) $9.41M-7.5%-3.5%38.8%

Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue147.79M113.83M120.79M119.91M112.82M
Cost of Revenue64.85M40.61M38.26M43.91M49.01M
Gross Profit82.94M73.22M82.53M76M63.81M
Gross Margin56.1%64.3%68.3%63.4%56.6%
Research & Development27.33M18.32M21.76M25.54M25.77M
Selling, General & Admin74.1M51.23M59.93M55.56M49.09M
Operating Expenses80.33M69.55M81.69M81.1M74.86M
Depreciation & Amortization14.32M14.49M14.22M8.12M5.73M
EBITDA(4.16M)18.81M17.37M5.36M(3.58M)
EBITDA Margin-2.8%16.5%14.4%4.5%-3.2%
Operating Income2.62M3.67M844K(5.1M)(11.05M)
Operating Margin1.8%3.2%0.7%-4.3%-9.8%
Interest Income—654K2.31M—0
Interest Expense—00—0
Other Income / Expenses(188K)654K2.31M2.34M1.74M
Income Before Tax2.43M4.32M3.16M(2.76M)(9.31M)
Pre-Tax Margin1.6%3.8%2.6%-2.3%-8.2%
Income Tax Expense(1.71M)2.12M6.6M6.06M672K
Net Income4.13M(14.86M)(82.67M)(56.39M)(10.88M)
Net Margin2.8%-13.1%-68.4%-47.0%-9.6%
EPS (Basic)0.29(1.02)(5.64)(3.83)(0.76)
EPS (Diluted)0.28(1.02)(5.64)(3.83)(0.76)
Weighted Avg Shares14.4M14.56M14.66M14.72M14.34M
Weighted Avg Shares (Diluted)14.63M14.56M14.66M14.72M14.34M

Anika Therapeutics, Inc.

NASDAQ:ANIK

Intrinsic Alpha fair value

Locked

Current Price

$13.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.